CNS Pharmaceuticals, Inc. (CNSP) research

CNS Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $5.32
As of: 2026-10-02

CNS Pharmaceuticals, Inc. (CNSP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.

As of 2026-10-02, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for CNSP. Method and limitations.

COMPANY DOSSIER

See the full CNSP dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for CNSP on one page. Preview it with sample data, then open it live with a free account.

Preview the CNSP dossier

Active signals for CNSP

mediumEARNINGS_MISS2026-08-12
Q2-2026: Missed consensus by 55.2%, EPS $-0.38 vs $-0.2448 estimate
All 2026-08-12 signals →
mediumEARNINGS_BEAT2026-06-20
Q2-2025: Beat consensus by 34.4% - EPS $-6.42 vs $-9.792 estimate
All 2026-06-20 signals →
mediumEARNINGS_BEAT2026-05-29
Beat consensus by 34.4% - EPS $-6.42 vs $-9.792 estimate
All 2026-05-29 signals →
mediumEARNINGS_BEAT2026-05-29
Q3-2025: Beat consensus by 20.4% - EPS $-5.76 vs $-7.2369 estimate
All 2026-05-29 signals →
mediumEARNINGS_MISS2026-05-29
Q4-2025: Missed consensus by 95.5% - EPS $-10.15 vs $-5.1918 estimate
All 2026-05-29 signals →

FREE, NO ACCOUNT

Every signal on CNSP, as it fires

You are seeing 5 of 6 signals recorded on CNSP since 2026-05-29.

The five above landed across 3 days. The other 1 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.

Recent SEC filings, CNSP

8-K2026-10-02
SEC EDGAR ↗
10-Q2026-08-12
SEC EDGAR ↗
8-K2026-07-02
SEC EDGAR ↗
10-Q2026-05-14
SEC EDGAR ↗
8-K2026-05-04
SEC EDGAR ↗
10-K2026-03-31
SEC EDGAR ↗
8-K2026-03-11
SEC EDGAR ↗
8-K2026-03-02
SEC EDGAR ↗
8-K2026-02-17
SEC EDGAR ↗
8-K2025-12-17
SEC EDGAR ↗

CNSP against its peers

CNSP's return on equity of -350.5% ranks in the 24th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.

Metric	CNSP	Peer median	Percentile	n
Revenue FY	n/a	1.8M	n/a	14
Gross margin	n/a	64.1%	n/a	8
Operating margin	n/a	-557.7%	n/a	12
Net margin	n/a	-459.1%	n/a	12
Return on equity	-350.5%	-197.1%	24	18

Peers (20): CLGN, AIM, IMNN, OSRH, ENSC, SKYE, CURX, XCUR, LEXX, ALZN, BOLT, LGVN, CELZ, CSCIF, KALA, RVPH, TRAW, EVGN, BGMS, IMRN. Left out: ENLV (no annual filing), LNAI (no annual filing), ENVB (no annual filing), LIANY (no annual filing), CUBT (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (CNSP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more CNSP signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CNSPand get the insider, 13F, options, and confluence read in one view.